Pipeline
Carna has leveraged its expertise in small molecule drug discovery to establish an innovative product pipeline focused on cancer and immune disorders. We achieve success by coupling our deep understanding of cell signaling with our extensive drug discovery expertise to generate therapeutics that provide new treatment options for patients with high unmet medical needs.
Science
Technology
Carna has developed a robust screening engine that makes it possible to identify new generation of small molecule drugs to treat patients afflicted with serious diseases.
Partnering
Carna is interested in partnering with pharmaceutical and biotechnology companies to develop our drug candidates. Carnaʼ s powerful drug discovery engine drives our pipeline expansion and the establishment of high-value partnerships.
Our drug discovery programs begin with screening our vast lead-like compound library, followed by optimization chemistry to identify highly selective drug candidates.
Topics
- New paper published in Bioorganic & Medicinal Chemistry Letters, in collaboration with Prof. Kinoshita of Osaka Metropolitan University
- Expanded Phase 1b Study Data for Docirbrutinib Demonstrate Robust Response and Favorable Safety Profile at EHA 2026
- Carna to Present Updated Results from Ongoing Phase 1b Study of Docirbrutinib, a Non-covalent Pan-mutant BTK Inhibitor, at the European Hematology Association Congress (EHA) 2026
- Publication of Preclinical and Early Clinical Data Demonstrating Best-in-Class, Pan-Mutant Activity of BTK Inhibitor Docirbrutinib
- Carna to Present Preclinical Findings on Monzosertib‑Induced Cancer Cell Death at AACR Annual Meeting